Skip to content

Welcome

Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

AAOA Member Benefits

  • Up to 60% discount for CME programs and free Annual Meeting. All AAOA’s CME programs meet ABOTOHNS Continuing Certification.
  • AAOA US ENT Affinity program, where AAOA members can gain savings on antigen, allergy supplies, and any of the other 5 service lines US ENT offers. For more email info@usentpartners.com.
  • Tools and resources to comply with US General Chapter 797 and practice management tools.
  • Advocacy support.
  • And much more! Learn More

PRACTICE MANAGEMENT CORNER

As part of our on-going member support, we are introducing a new website feature to help with common practice management challenges. We welcome your input with questions or challenges you would like to address. Read More

ADVOCACY UPDATES

Penicillin Allergy Verification and Evaluation (PAVE) Act

Penicillin Allergy Verification and Evaluation (PAVE) Act to be introduced by Rep. Bucshon. AAOA is one…

Read more

CMS Released the Annual Medicare Physician Fee Schedule Proposed Rule

On July 10, the Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician…

Read more

Latest on Federal Issues

This blog will feature weekly updates from our Socioeconomic Committee and Health Policy team to…

Read more

Upcoming Dates

08/02/24: Scientific Abstract Submission Deadline
Learn more

12/01/24: Research Grant Cycle
Learn more

04/01/25: Fellow Exam Application Deadline
Learn more

06/01/25: Research Grant Cycle
Learn more

EDUCATION

AAOA Annual Meeting

Register for FREE* to attend the 2024 AAOA Annual Meeting in-person, in Las Vegas, or virtually!

*The 2024 AAOA Annual Meeting is FREE to all AAOA members in good standing

RESIDENTS

For information about Resident membership, opportunities, DosedDaily, research grants, and other resources. Learn More

IFAR

Available Now

aaoaf-ifar

IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2024 AAOA Annual Meeting - Hybrid
November 8-10, 2024
Four Seasons Hotel Las Vegas
Learn More and Register 

Coming Soon! New Explorers Course — Hybrid
90-days Access Feb 27 – May 27, 2025 
March 27-29, 2025 - Live
The Hythe, Vail, CO
Book Your Room

2025 AAOA Basic Course in Allergy & Immunology - Hybrid
90-days Access June 10 – Sep 15, 2025
July 10-12, 2025 - Live
The Chateaux Deer Valley, Park City, UT
Book Your Room

USP 797 Online Module
Learn More and Register

AAOA Educational Stacks
Available Now!

News and Updates

CEO Update, September 2024

“Life starts all over again when it gets crisp in the Fall”. F. Scott Fitzgerald…

Read more

ABOHNS Practice Analysis Job Task Analysis Survey

On September 24 the ABOHNS initiated a Practice Analysis (Job Task Analysis) Survey. All ABOHNS…

Read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

Congress Makes Changes to MACRA

The second year of the Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA) began in January, but in February, Congress responded to concerns from the physician community and made changes to the Merit-Based Incentive Payment System (MIPS) one of the two tracks in the QPP. These changes provide the Centers for Medicare and Medicaid Services greater flexibility in implementing the program.
They include:

  • The original MACRA statute included the cost of physician administered drugs in the calculation of MIPS bonuses and penalties. This differed from how these calculations were made under the legacy quality programs, like the Physician Quality Reporting System. As a result of this legislative change, physician administered drug costs will be excluded from the MIPS bonus and payment adjustment calculations.
  • CMS is still in the process of developing episode specific cost measures to evaluate clinicians’ resource use as part of the Cost category in MIPS. Beginning in year 3 of the program, CMS was statutorily mandated to count cost as 30% of a clinician’s score. Congress has now provided the agency with more flexibility allowing the weight to be set at no less than 10% for years 2 through 5 of the program.
  • Similar changes were made to the MIPS performance threshold, the score at which penalties are assessed to those below and bonuses to those above. CMS will now have the flexibility to set this threshold for years 2 through 5 before requiring it to be set at either the mean or median of the performance scores.

These changes will allow those participating in MIPS to more gradually transition into the MIPS program and gain a better understanding of they can succeed in this new value-based model. The physician community is very pleased that Congress took action to make these changes.

CMS Launches Patients Over Paperwork Initiative

Last fall CMS launched a new initiative called “Patients Over Paperwork” with the aim of reducing burdensome regulations. CMS has established a process to evaluate and streamline regulations to reduce burden on physicians and improve the beneficiary experience. Issues that are being considered as part of the initiative include:

  • Reducing the burden associated with the Quality Payment Program
  • Improving the medical review process
  • Reducing documentation requirements
  • Improving Patient Access to their Electronic Data

As part of the initiative, CMS is accepting feedback from the public and when appropriate making changes in response. For instance, the agency consolidated the QPP data submission process allowing physicians to submit all over their MIPS data through one site.

Sign up for the monthly newsletters on this initiative here.

Congress Struggles to Address Drug Prices as White House Prepares to Release Plan

Both Congress and the White House continue to express concern about the high cost of prescription drugs and the impact on patient access. When drug price spikes make the news, like they did with the EpiPen, Congress takes notice and holds hearings. The President has been stating that controlling drug costs is a priority since the campaign. Despite all the interest, no action has been taken.

In a midterm election year, Congress is unlikely to pass significant legislation on this topic, but the committees of jurisdiction continue to meet with stakeholders to explore the issue and brainstorm solutions. The first real action on this issue will come next week when the White House unveils its plan to curb the growth of drug prices.

One of the White House proposals may be to allow pharmacy benefit managers to negotiate prices for some Medicare Part B drugs similar to what they do in Part D. Another option may be to share rebates with seniors at the point of sale. The President’s budget request called for cutting doctors’ Part B reimbursement for administering drugs and testing the approach in a demonstration. CMS could devise a formula to limit Part B drug reimbursement for certain classes of drugs. It should be noted the Obama administration proposed a Part B drug demonstration that would have limited provider reimbursement for drug administration and received serious criticism from stakeholders on this proposal that was never finalized.

The White House proposal may include controversial legislative changes like capping Medicare beneficiaries’ annual out-of-pocket spending and gradually making plans pay for 80 percent of the spending in catastrophic coverage which is currently capped at 15 percent. Another legislative approach is to count discounts toward beneficiary out-of-pocket spending which would increase beneficiary costs before reaching catastrophic coverage. This would discourage the use of expensive Part D drugs.

Whatever policies are included in the White House proposal, it is clear that there is no easy fix for patients who continue to struggle with the high and sometimes unpredictable costs of prescription drugs.

Back To Top